After a flurry of media reports, President Trump took to social media to officially nominate Dr. Heidi Overton as the next FDA commissioner.

Dr. Overton is a board-certified physician in public health and preventive medicine with a doctorate in clinical investigation from Johns Hopkins University. She first joined the White House as a fellow during President Trump’s first term, then held multiple roles at the Trump-aligned America First Policy Institute.

At present, Dr. Overton serves as the deputy assistant to the president for domestic policy, where her portfolio includes vaccine policy, reproductive health and IVF services. Proponents of her candidacy have credited her with successfully translating administration health priorities into legally sound and medically defensible policy.

A recent profile from The Atlantic describes Dr. Overton as one of the White House’s “gatekeepers” for MAHA-related policy. Critics of the choice have accused her of being an “insider” pick that could check the power of HHS Secretary Robert F. Kennedy Jr on MAHA priorities. Of note, Kennedy offered congratulations to Dr. Overton and called the search for an FDA commissioner “one of the toughest decisions of my tenure.”

Wall Street analysts believe Dr. Overton’s leadership could boost FDA support for psychedelic treatments and non-opioid pain medicines. However, her nomination will face real scrutiny from Congress; the chair of the Senate’s health committee, Bill Cassidy, R-La., called her lack of experience and previous vaccine work “almost disqualifying.”

– Leslie Isenegger & Andrew Wishon, Real Chemistry

Germany’s recent adoption of the GKV-Beitragssatzstabilisierungsgesetz has drawn a strong reaction from the pharmaceutical industry and continues to attract attention in both German and international media.

On July 30, a new Statutory Health Insurance Contribution Rate Stabilization Act came into force in Germany. Its aim is to target a projected €19 billion healthcare funding gap through a savings package that features increased pharma discounts and a raise in the mandatory manufacturer rebate on patented drugs from 7% to 15.5%.

The German industry organization “Pharma Deutschland” on August 12 called for a halt on “investment barriers” and published a white paper. It outlines the following arguments against the German government’s planned healthcare strategy, namely the need to:

• Strengthen Germany as a pharmaceutical industry hub
• Secure the domestic supply of innovative medicines
• Accelerate regulatory approval and access procedures
• Incentivize research and innovation
• Expand prevention and over-the-counter medication options.

Thereafter the Financial Times reported that Germany’s attempts to curb healthcare costs could undermine the country’s globally competitive pharma industry, ceding “further ground to the U.S. and China.”

Furthermore, as we go to press, Germany’s statutory health insurers published their results for the first half of 2026, reporting a significant surplus. Early reactions from stakeholders suggest this may mean the budget deficit is not what was originally projected. Yet, insurers caution that this surplus is by no means a signal for relaxation. Instead, they ask for further savings, since numbers show an unmitigated increase in healthcare spend (up about 7.7% in the first quarter alone).

What’s clear is that further debate between policymakers, insurers and industry stakeholders will most likely continue in Germany over the coming months.

– Julia Scheiderer & Francesca Boldrini, Real Chemistry

• August 24 – deadline for drug manufacturers to submit 340B rebate pilot plans, HRSA
• August 27 – webinar on proposed changes to 340B and potential implications for patients, National Health Council

• “At a time when they need clear, calm, and evidence-based advice, our federal leaders are stoking fears, sowing confusion, and exploiting the desire that all parents share to keep their children safe and healthy. Parents, and children, deserve better.” – Dr. Andrew Racine, STAT
• “The U.S. can outpace the rest of the world in this next frontier of healthcare, but only with a policy environment that encourages innovation and enables American companies to compete on equal footing with their global counterparts.” – David Mansdoerfer, The Hill
• “The other day, the White House proclaimed on social media that the declining drug price index was an example of ‘promises made, promises kept.’ But more than a promise kept to Americans, it’s really a promise kept to the Republican Party. We’re still waiting for Trump to deliver.” – Ed Silverman, STAT
• “For decades, U.S. drug policy has balanced temporary market exclusivity for innovators with vigorous generic competition afterward. The IRA risks upsetting that balance. Washington can mandate a lower price today. It cannot mandate robust competition tomorrow.” – Sally Pipes, Forbes

• Real Chemistry’s Frank Mazzola says pharma marketing is poised to become one of advertising’s most creative categories within a decade, urging agencies to move beyond generic patient-journey tropes. Fierce Pharma: Inside agency view: Real Chemistry’s Frank Mazzola on audience nuance and rewarding creativity.
• PhRMA’s four-month search for a new CEO reportedly includes a mix of Republican-aligned candidates, including former lawmakers and past Trump administration officials. Endpoints: PhRMA considers a grab-bag of Republican policy wonks, former lawmakers for CEO post.
• A federal appeals court sent part of Teva’s lawsuit on Medicare price negotiations back to a lower court to reconsider CMS’ “bona fide marketing” standard for generics. Endpoints: Federal appeals court revives part of Teva’s IRA case as Austedo price cuts loom.
• CDC Director Erica Schwartz told staff in her first all-hands meeting that she’s prepared to push back against HHS Secretary Kennedy if needed. STAT: New CDC director tells staff she is prepared to speak ‘truth to power.’
• While the White House is taking credit for a reported drop in drug prices, experts cite Medicare changes and rising generic/biosimilar competition. Endpoints: Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy lifting.
• Nearly 50 drug launches have been delayed or canceled in Canada over the past year as manufacturers weigh the implications of U.S. MFN drug pricing. CityNews Toronto: U.S. policy compelling some drug companies to stall medicine rollouts in Canada.
• Cost and perception are emerging as key battlegrounds in the GLP-1 market, with nearly three-quarters of patients who discontinue treatment citing price. PharmaVoice: How cost and perception could reshape the GLP-1 market.
• Japan’s new “Honebuto” economic policy blueprint is a push to position pharma as a strategic industry through innovation incentives and AI-driven care, though industry groups say pricing reforms are still needed. Pink Sheet: Japan Policies Position Pharma As Key Industry. But Can They Ensure Value?